\BOOKMARK [1][-]{section.1}{Introduction}{}% 1
\BOOKMARK [1][-]{section.2}{Methods}{}% 2
\BOOKMARK [2][-]{subsection.2.1}{Datasets}{section.2}% 3
\BOOKMARK [2][-]{subsection.2.2}{Model}{section.2}% 4
\BOOKMARK [3][-]{subsubsection.2.2.1}{Spatial proteomics mixture model}{subsection.2.2}% 5
\BOOKMARK [3][-]{subsubsection.2.2.2}{Bayesian inference and convergence}{subsection.2.2}% 6
\BOOKMARK [3][-]{subsubsection.2.2.3}{Visualising patterns in uncertainty}{subsection.2.2}% 7
\BOOKMARK [3][-]{subsubsection.2.2.4}{Uncertainty quantification}{subsection.2.2}% 8
\BOOKMARK [3][-]{subsubsection.2.2.5}{Applying the model in practice}{subsection.2.2}% 9
\BOOKMARK [2][-]{subsection.2.3}{Validating computational approaches}{section.2}% 10
\BOOKMARK [3][-]{subsubsection.2.3.1}{Artificial masking of annotations to recover experimental design}{subsection.2.3}% 11
\BOOKMARK [3][-]{subsubsection.2.3.2}{The Human Protein Atlas}{subsection.2.3}% 12
\BOOKMARK [3][-]{subsubsection.2.3.3}{Gene Ontology \(GO\) term enrichment}{subsection.2.3}% 13
\BOOKMARK [3][-]{subsubsection.2.3.4}{Robustness across multiple MS-based spatial proteomics datasets}{subsection.2.3}% 14
\BOOKMARK [1][-]{section.3}{Results}{}% 15
\BOOKMARK [2][-]{subsection.3.1}{Validating experimental design in hyperLOPIT}{section.3}% 16
\BOOKMARK [3][-]{subsubsection.3.1.1}{Human bone osteosarcoma \(U-2 OS\) cells}{subsection.3.1}% 17
\BOOKMARK [3][-]{subsubsection.3.1.2}{Pluripotent mESCs \(E14TG2a\)}{subsection.3.1}% 18
\BOOKMARK [2][-]{subsection.3.2}{Uncovering additional sub-cellular structures}{section.3}% 19
\BOOKMARK [3][-]{subsubsection.3.2.1}{U-2 OS cell line revisited}{subsection.3.2}% 20
\BOOKMARK [3][-]{subsubsection.3.2.2}{Saccharomyces cerevisiae}{subsection.3.2}% 21
\BOOKMARK [3][-]{subsubsection.3.2.3}{Fibroblast cells}{subsection.3.2}% 22
\BOOKMARK [2][-]{subsection.3.3}{Refining annotation in organellar maps}{section.3}% 23
\BOOKMARK [3][-]{subsubsection.3.3.1}{HeLa cells \(Itzhak et. al 2016\)}{subsection.3.3}% 24
\BOOKMARK [3][-]{subsubsection.3.3.2}{Mouse primary neurons and HeLa cells \(Hirst et. al 2018\)}{subsection.3.3}% 25
\BOOKMARK [1][-]{section.4}{Comparison between Novelty TAGM and phenoDisco}{}% 26
\BOOKMARK [1][-]{section.5}{Improved annotation allows exploration of endosomal processes}{}% 27
\BOOKMARK [1][-]{section.6}{Discussion}{}% 28
\BOOKMARK [1][-]{section.7}{Appendix}{}% 29
\BOOKMARK [2][-]{subsection.7.1}{mESC chromatin enrichment validation}{section.7}% 30
\BOOKMARK [2][-]{subsection.7.2}{Uncovering additional annotations in fibroblast cells}{section.7}% 31
\BOOKMARK [3][-]{subsubsection.7.2.1}{HCMV-infected fibroblast cells}{subsection.7.2}% 32
\BOOKMARK [3][-]{subsubsection.7.2.2}{Fibroblast cells without infection}{subsection.7.2}% 33
\BOOKMARK [2][-]{subsection.7.3}{Additional organellar map datasets}{section.7}% 34
\BOOKMARK [3][-]{subsubsection.7.3.1}{Mouse primary neurons}{subsection.7.3}% 35
\BOOKMARK [3][-]{subsubsection.7.3.2}{HeLa cells \(Hirst et. al 2018\)}{subsection.7.3}% 36
\BOOKMARK [2][-]{subsection.7.4}{Handling label switching}{section.7}% 37
\BOOKMARK [2][-]{subsection.7.5}{Summarising posterior similarity matrices}{section.7}% 38
\BOOKMARK [2][-]{subsection.7.6}{Details of MCMC}{section.7}% 39
\BOOKMARK [2][-]{subsection.7.7}{Further details of endosomal proteins}{section.7}% 40
\BOOKMARK [2][-]{subsection.7.8}{Summary of convergence diagnostics}{section.7}% 41
\BOOKMARK [2][-]{subsection.7.9}{Prior specification and sensitivity}{section.7}% 42
\BOOKMARK [3][-]{subsubsection.7.9.1}{Detailed prior specification}{subsection.7.9}% 43
\BOOKMARK [3][-]{subsubsection.7.9.2}{Relative proportions of labelled and unlabelled data}{subsection.7.9}% 44
\BOOKMARK [1][-]{section.8}{Acknowledgements}{}% 45
\BOOKMARK [1][-]{section.9}{Data Availability}{}% 46
